Ranbaxy Fights To Convince Sales Staff No Changes With Daiichi Buy
This article was originally published in PharmAsia News
Even as Japan's Daiichi Sankyo's bid to buy India's Ranbaxy Laboratories neared completion, sales personnel, some of them with the company for more than two decades, face a new way in doing business. Ranbaxy's sales force numbers about 2,000, but as part of Daiichi it now is representing the world's 15th largest drug maker. The head of that force, Vivek Sawant, says physicians at first had a hard time believing the Ranbaxy operation would remain unchanged by the merger. Some doctors, and the medical representatives who deal with them, had problems with the idea of losing a local company to a foreign owner, but thanks to a strong effort, Ranbaxy believes it has convinced physicians its products and service would remain unchanged. (Click here for more
You may also be interested in...
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.